11 Patients with a family history of diabetes, age > 45 years, ATSI and obesity are at an increased risk for the future development of diabetes and as such consideration for screening all high-risk patients with a 2 h OGTT rather than just two fasting plasma glucose measurements should be made.12 Databases searched: MeSH terms and text words for kidney transplantation were combined with MeSH terms and text
words for living donor and combined with MeSH terms and text words for glucose intolerance. find more The search was carried out in Medline (1950–July Week 3, 2008). The Cochrane Renal Group Trials Register was also searched for trials not indexed in Medline. Date of searches: 24 July 2008. There are no published studies that could be located that
quantify the risk to donors with impaired glucose tolerance prior to transplant nephrectomy. This likely reflects the common practice of avoiding these donors. Due to the lack of information on the outcome in living kidney donors with Selleckchem Regorafenib pre-donation impaired glucose tolerance we commenced our review by examining the incidence of type 2 diabetes mellitus in healthy living kidney donors (i.e. normal blood pressure, glomerular filtration rate > 80 mL/min and normal amount of proteinuria pre-donation). There are 11 studies that describe the development of diabetes mellitus following living kidney donation 3-mercaptopyruvate sulfurtransferase in donors.13–23 These studies describe an incidence of 1.5–7.4% with a follow
up of more than 20 years in some studies. All of the studies suffer with the following methodological problems: 1 cross-sectional – none were designed to follow donors prospectively from the time of transplant and most examine donors cross-sectionally post transplant, Fehrman-Ekholm et al. described 348 Swedish living kidney donors at a mean of 12 years post-donation. They represented 87% of the total living donors from Stockholm between 1964 and 1995 who were still alive. Despite normal OGTT for all donors at baseline, six developed type 2 diabetes mellitus.13 In another study, the authors were able to obtain information on 33% (256/773) of living kidney donors over 20 years post-donation. Of these, 19 developed type 2 diabetes mellitus, despite the 10 with a positive family history having negative baseline OGTT.14 It is unclear the effect donation has on the incidence of developing diabetes mellitus due to the lack of suitable controls. Diabetic nephropathy is currently the most common cause of end-stage kidney disease in developed countries. The risk of developing diabetic nephropathy varies between studies, with one study documenting a prevalence of 25.4% for microalbuminuria and <10% for macroalbuminuria or end-stage kidney disease in 27 805 type 1 diabetic patients.24 A similar prevalence was observed in type 2 diabetes.